Volitionrx (VNRX) Common Equity (2011 - 2025)

Volitionrx has reported Common Equity for 12 years, with the latest figure at -$35.6 million in Q4 2025.

• For the quarter ending Q4 2025, Common Equity fell 36.33% year-over-year to -$35.6 million; the trailing twelve-month figure through Dec 2025 stood at -$35.6 million (down 36.33% YoY), and the FY2025 full-year result was -$35.6 million, down 36.33% from the prior year.
• Common Equity for Q4 2025 stood at -$35.6 million, down from -$34.6 million in the prior quarter.
• The five-year high for Common Equity was $31.2 million in Q1 2021, with the low at -$35.6 million in Q4 2025.
• Historically, Common Equity has averaged -$5.9 million across 5 years, with a median of -$3.1 million in 2022.
• Annual changes were most pronounced in 2021 — Common Equity jumped 239.27% — and 2024, when it tumbled 694.03%.
• Volitionrx's Common Equity stood at $17.7 million in 2021, then slumped by 117.64% to -$3.1 million in 2022, then tumbled by 178.62% to -$8.7 million in 2023, then sank by 199.67% to -$26.1 million in 2024, then slumped by 36.33% to -$35.6 million in 2025.
• The last three Common Equity figures came in at -$35.6 million (Q4 2025), -$34.6 million (Q3 2025), and -$33.1 million (Q2 2025), per Business Quant data.